UnitedHealth Maintaining Tier 2 Formulary Status For Vytorin
Executive Summary
UnitedHealth Group will retain the current tier 2 formulary placement - preferred brand - for Vytorin (ezetimibe/simvastatin) in both its commercial and Medicare Part D formularies because the recently-released ENHANCE data do not indicate any safety issues with the drug, the firm said
You may also be interested in...
UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009
National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.